Researchers at the University of Hong Kong's LKS Faculty of Medicine report that a widely prescribed class of bone drugs, nitrogen-containing bisphosphonates (NBPs), was associated with lower dementia risk among older adults. The findings, published in Alzheimer's & Dementia, compared patients with osteoporosis or fragility fractures who took NBPs with those who took no osteoporosis medication or other types of osteoporosis drugs.
The study drew on electronic medical records from more than 120,000 Hong Kong patients aged 60 and older, covering 2005 through 2020. Patients taking NBPs had a 16% lower risk of developing Alzheimer's disease and related dementias compared with patients who received no osteoporosis medication. The gap widened when NBP users were compared with people taking other osteoporosis drugs, where dementia risk was 24% lower. Women and patients who had experienced hip fractures appeared to show particularly strong associations.
The authors have a reason to look at these drugs in particular. Osteoporosis and dementia often affect the same older adults and share risk factors such as older age, being female, and low physical activity. The team's earlier work had found that osteoporosis and fractures are independent risk factors for dementia, and that people already living with dementia face a higher likelihood of falls and broken bones.
The researchers estimated that treating 48 patients with NBPs over five years could potentially prevent one case of dementia. Professor Cheung Ching-lung, the study's lead researcher, said the results support the idea that a familiar treatment might offer two benefits, stronger bones and possibly a protective effect on the brain. Because the work is observational, it cannot show that the drugs themselves prevent dementia. The authors say further studies are needed to determine whether NBPs can directly prevent or delay cognitive decline.